A 2026 laboratory study suggests tadalafil may affect skeletal-muscle cell growth and early myogenic markers — but also delays muscle-cell maturation. Here is what the findings mean, and why human benefits remain unproven.
A 2026 study found that tadalafil changed the behaviour of mouse-derived C2C12 muscle cells in the laboratory: cell proliferation and survival increased, and some early muscle-development markers rose. However, terminal differentiation into mature muscle fibres was also delayed.
This is an interesting biological signal — not proof that tadalafil repairs injured muscles, increases strength, or treats muscle-wasting disease in people. Tadalafil remains a prescription medicine for specific approved indications, not an established muscle-regeneration or bodybuilding treatment.
Headlines about a "muscle-building drug" travel fast, and every few months a new study revives the idea that a familiar pill could double as a recovery aid. The latest one concerns tadalafil — better known by its brand names for erectile dysfunction — and skeletal muscle. This article explains, in plain language, what the 2026 research on tadalafil and muscle regeneration actually shows, what it does not show, and why the difference matters if you are considering tadalafil for muscle repair, training recovery or muscle wasting.
Tadalafil is best known as a phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction and, in appropriate formulations and settings, pulmonary arterial hypertension and other approved indications depending on the country. Researchers are also examining how the nitric oxide–cyclic guanosine monophosphate (NO–cGMP) signalling pathway may affect tissues beyond its established clinical uses.
A new 2026 laboratory study adds to this research. It investigated prolonged tadalafil exposure in C2C12 cells, a widely used mouse-derived model for studying skeletal-muscle development. The findings raise questions about myogenesis — the process through which precursor cells develop into muscle cells — but they do not establish a treatment for human muscle injury or muscle loss.
The paper, "Prolonged tadalafil exposure promotes skeletal muscle myogenesis and regulates early myogenic markers activation in C2C12 cell lines," reported that researchers exposed C2C12 cells to 1 micromolar tadalafil for up to seven days.
The reported findings included:
That final point matters. More precursor-cell activity does not automatically mean better muscle regeneration. Successful regeneration requires a coordinated sequence of cell activation, proliferation, differentiation, and functional integration. A compound that increases early-stage activity while delaying maturation may have complex effects that require further investigation.
No — not on the available evidence. The 2026 experiment was conducted in cultured cells, not in people recovering from injury, surgery, immobilisation, or a muscle-wasting disorder. Cell-culture findings can help identify biological mechanisms, but they cannot establish a safe dose, a clinically meaningful benefit, or long-term outcomes in patients.
Earlier research has explored possible effects of tadalafil on skeletal-muscle metabolism. A small 2017 study involving 43 men with mild erectile dysfunction and/or lower urinary tract symptoms reported a change in abdominal lean mass in the group receiving daily tadalafil over two months; the measured change returned towards baseline after treatment withdrawal. The study was small and was not a clinical trial of muscle regeneration after injury. It does not prove that tadalafil increases muscle strength or produces reliable muscle growth in healthy people.
A 2023 review also discussed possible interactions between tadalafil, skeletal-muscle metabolism, insulin-related signalling, steroid hormones, and exercise adaptation. Reviews can help map hypotheses, but they do not replace large, well-designed clinical trials.
A Doktorly care manager can review your medication list, flag interactions, and arrange a consultation with a licensed prescriber — before you change anything.
Book a Consultation Browse MedicationsTadalafil inhibits PDE5, an enzyme that breaks down cGMP. By inhibiting this enzyme, tadalafil can prolong cGMP-related signalling in tissues where the pathway is active. Researchers are studying whether related pathways may influence:
These are research questions, not established therapeutic outcomes. Effects seen in one cell model may not translate to human skeletal muscle, and changes in molecular markers do not necessarily predict improved mobility, strength, recovery time, or quality of life.
It is too early to say. Before tadalafil could be recommended for muscle regeneration, researchers would need evidence from appropriately designed human studies. Such studies would need to define the target condition, assess clinically relevant outcomes — such as muscle strength, physical function, recovery, and adverse events — and establish whether any benefit outweighs the risks.
Research in cultured cells is an early step in the evidence pathway. It should not be presented as proof that tadalafil treats sarcopenia, muscular dystrophy, sports injuries, post-operative muscle loss, or delayed recovery.
Tadalafil can cause headache, flushing, indigestion, nasal congestion, back pain, and other adverse effects. It can also cause a dangerous drop in blood pressure when combined with nitrate medicines; it may interact with other medicines and may be unsuitable for some people with cardiovascular conditions. Sudden vision or hearing changes and an erection lasting more than four hours require urgent medical assessment.
Do not start tadalafil, change a prescribed dose, or combine it with performance-enhancing substances for muscle growth without a clinician's advice. The laboratory study did not establish a dose for people, and taking more is not a way to reproduce cell-culture results.
Not proven in humans. The 2026 evidence comes from mouse-derived C2C12 cells in a dish, not from people. A small 2017 study of 43 men reported a change in abdominal lean mass during two months of daily tadalafil that moved back towards baseline after treatment stopped. No well-designed clinical trial has shown that tadalafil increases muscle size or strength in healthy people.
No. The available studies are cell-culture experiments, a small lean-mass study, and narrative reviews. None of them measured recovery from injury, surgery, immobilisation or muscle-wasting disease in people. Cell findings cannot establish a safe dose, a clinically meaningful benefit, or long-term outcomes in patients.
Researchers exposed C2C12 cells to 1 micromolar tadalafil for up to seven days. Treated cells proliferated more and survived better; early myogenic markers such as Pax7 and Myf6 stayed elevated; Sirt3 and IL6 expression rose while myostatin and TGF-β fell. However, terminal differentiation was delayed and fewer mature, multinucleated myotubes formed — so the effect was mixed, not a regeneration benefit.
It is not an approved or established muscle-building treatment, and taking it for this purpose without medical supervision is not safe. Tadalafil can cause headache, flushing, indigestion, nasal congestion and back pain; it causes a dangerous blood-pressure drop with nitrate medicines, can interact with other drugs, and is unsuitable for some people with cardiovascular conditions. Sudden vision or hearing changes or an erection lasting more than four hours need urgent medical assessment. The laboratory study established no dose for people.
The new 2026 study makes tadalafil and skeletal-muscle biology a worthwhile research topic, but the headline needs careful wording. In a mouse-derived cell model, tadalafil increased proliferation and altered early myogenic markers while also delaying terminal differentiation. This is a mixed, early-stage finding — not proof of muscle regeneration in humans. For now, tadalafil should be used only for an appropriate medical indication under professional guidance, not as a muscle-repair or bodybuilding supplement.